Indus Capital Partners, LLC I Mab Transaction History

Indus Capital Partners, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$8.27 - $18.43 $2.17 Million - $4.84 Million	-262,685 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$12.54 - $46.93 $1.27 Million - $4.76 Million	101,393 Added 62.86%	262,685 $4.27 Million
Q4 2021 Feb 14, 2022	SELL	$45.28 - $74.5 $3.85 Million - $6.33 Million	-84,964 Reduced 34.5%	161,292 $7.64 Million
Q3 2021 Nov 15, 2021	SELL	$57.18 - $84.43 $3.6 Million - $5.31 Million	-62,939 Reduced 20.36%	246,256 $17.9 Million
Q2 2021 Aug 16, 2021	SELL	$47.86 - $83.95 $8.94 Million - $15.7 Million	-186,794 Reduced 37.66%	309,195 $26 Million
Q1 2021 May 14, 2021	BUY	$44.38 - $63.97 $16.1 Million - $23.3 Million	363,453 Added 274.23%	495,989 $24 Million
Q4 2020 Feb 16, 2021	BUY	$32.94 - $47.15 $1.03 Million - $1.47 Million	31,183 Added 30.77%	132,536 $6.25 Million
Q3 2020 Nov 13, 2020	BUY	$27.46 - $47.03 $2.78 Million - $4.77 Million	101,353 New	101,353 $4.77 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $76.5M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Indus Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Indus Capital Partners, LLC with notifications on news.